Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.
Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer
Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer
The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal cancer on October 17, 2024.
Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer
The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.